Abstract: Platelets play a vital role in normal hemostasis to stem blood loss at sites of vascular injury by tethering and adhering to sites of injury, recruiting other platelets and blood cells to the developing clot, releasing vasoactive small molecules and proteins, and assembling and activating plasma coagulation proteins in a tightly regulated temporal and spatial manner. In synchrony with specific end products of coagulation, primarily cross-linked fibrin, a stable thrombus quickly forms. Far beyond physiological hemostasis and pathological thrombosis, emerging evidence supports platelets playing a pivotal role in vascular homeostasis, inflammation, cellular repair, regeneration, and wide range of autocrine and paracrine functions. In essence, platelets play both structural and functional roles as reporters, messengers, and active transporters surveying the vasculature for cues of environmental or developmental stimuli and participating as first responders.
It is certain that no constituent of the blood is unimportant and so I will, in conclusion, draw attention, with some emphasis, to a normal constituent of the blood which until now has almost been unnoticed.
-Max Schultze, 1865
Brief History of Platelets
The first detailed description of platelets has been attributed to Schultze 2 who recognized them as a normal constituent of circulating blood in 1865. 3 Less than 2 decades later, Bizzozero 4 observed platelets microscopically in the circulation of living animals and in blood removed from blood vessels. He subsequently went on to show, for the first time, that platelets were the initial cellular component of blood to adhere to damaged blood vessel walls both in vivo and in vitro and stated, "under normal circumstances platelets float isolated in plasma, but once subjected to an influence that causes thrombosis, they adhere to one another to form an accumulation. The blood platelets, while otherwise heard along in the circulation are held up by other platelets that they come into contact [with them] as they become stickier than they are under normal conditions." Moreover, he went on to describe platelet adherence to threads later recognized to be fibrin. Wright 5 examined blood smears using the stain named for him and used the term platelets in a 1910 publication, which has become the universally accepted term.
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Overview of Platelet Function
Platelets play an essential role in sensing and responding to perturbations in the blood and vasculature. Their reaction to environmental cues has both local and systemic consequences. As purveyors of the vascular space, they transmit information broadly and are the key participants in developmental processes, hemostasis, thrombosis, and host responses.
Platelet function is tightly regulated within the vasculature, and several factors (eg, NO, prostacyclin, and ADPase activity present on or released by vascular endothelium) 6 maintain them in a normally resting, discoid-shaped state ( Figure 1 ). Adherence to damaged or inflamed endothelium, uncovered subendothelial tissue, and exposure to nonphysiological shear flow conditions activate platelets. 7 Local generation of thrombin and other platelet activators perpetuate intraplatelet signaling systems. Platelets themselves respond to these and other stimuli by secreting prothrombotic proteins from dense and α-granules and by changing morphology through rearrangement of the cytoskeletal network. Secretion of prothrombotic proteins and signals elicits a second wave of platelet activation and propogates inside-out signaling to alter the configuration of integrins on the platelet surface and assume a high affinity state that reinforces intracellular signaling ( Figure 1 ). Activation of integrin αIIbβ3 and subsequent binding of the multivalent ligand fibrinogen that bridges adjacent platelets is essential for platelet aggregation. 8 To achieve the tight balance required for hemostasis, platelet activation is closely controlled by a series of highly regulated receptor-ligand interactions. Among the plasma and extracellular matrix proteins recognized by platelets include collagen, vWF (von Willebrand factor), fibronectin, and thrombospondin. The more abundant platelet-adhesive receptors include GP (glycoprotein) VI, GP Ib/V/IX, and integrin αIIbβ3. Exposed subendothelial collagen is recognized by integrin α2β1 and GPVI, the latter of which forms a hemiplatelet immunoreceptor tyrosine-based activation motif (ITAM) signaling complex with FcRy. 9, 10 Tyrosine phosphorylation of FcRy on collagen binding to GPVI leads to cascade activation of Syk kinase, PLCγ2 (phospholipase C γ2), and PI-3K (phosphatidylinositol 3-kinase), which results in diacylglycerol/protein kinase C, IP 3 (inositol trisphosphate)/calcium mobilization, and ultimately integrin activation. 11 vWF-a GP ranging in size from 600 000 to 20 million Da-participates actively in platelet adhesion to either injured or disrupted vascular surfaces, activation, and high-shear state platelet aggregation. 12 Each monomer of vWF has 3 functional domains that are important for primary hemostasis, and pathological thrombosis-domain A1 binds platelet GP Ibα receptors; domain A3 binds to collagen on damaged blood vessels; and domain A2 contains cleavage sites that are exposed by shear of vWFs induced conformational changes. 13, 14 This cleavage process is important to avoid unregulated thrombosis because HMWMs (high-molecular weight multimers) are highly active and propagate platelet thrombus formation through activation, adhesion, and aggregation of platelets. Under conditions of normal blood flow, HMWMs are folded and inactive, but under conditions of shear stress as occurs with vascular injury, this molecule is stretched, activates and establishes a template for thrombus formation at sites of injury. As a regulatory mechanism, stretching of vWF unfolds the tertiary structure of the protein to induce a conformational change in the A2 domain that predisposes HMWM cleavage by the metalloprotease ADAMTS13 (disintegrin-like and metalloproteinase with thrombospondin repeats-13) into smaller multimers or monomers with reduced thrombogenicity.
Interactions of GP Ib with vWF and other ligands can trigger intracellular signaling, through the Src-kinase family and other pathways, with consequent integrin activation. 15 Activated integrins, in turn, mediate outside-in signaling on ligand binding and with clustering of integrin-ligand complexes on the platelet surface. 16 In parallel with adhesivemediated activation, soluble agonists elicit platelet activation, often through actions on GPCRs (G-protein-coupled receptors). 17 Thrombin has a unique mechanism of activating the PAR (protease-activated receptor) that involves release of an amino acid peptide to create a tethered ligand at the terminal region of the receptor that binds back on itself to stimulate GPCR signaling. Additional agonists, such as ADP and serotonin, are released from storage granules during platelet activation and interact with their GPCRs to stabilize thrombus growth. In the case of ADP, the predominate receptors are P2Y1 and P2Y12, which act through G q and G i , respectively. 18 The fusion of α-granules with the plasma membrane during platelet activation results in expression of P-selectin and other GPs that participate in pathophysiology interactions, such as with leukocytes and other cells. Arachidonic acid is generated during platelet activation and is converted to thromboxane A 2 , another potent agonist, leading to continued platelet activation and the ultimate stage of aggregation through fibrinogenintegrin αIIbβ3 bridges among adjacent platelets 19 ( Figure 1 ). Platelet aggregation is stabilized by several subsequent interactions mediated by Gas6 receptors, 20 ephrins, semaphorins, and other molecules. 21 Additionally, platelets possess mechanisms for interplatelet communication, such as through connexins discussed below.
Polyphosphates, which are polymers of repeating units of inorganic phosphate residues linked by phosphoanhydride bonds, were identified in a landmark study by Ruiz et al, 22 to reside within platelet dense granules and subsequently shown to be released after activation with thrombin, ADP and, collagen 23 and contribute to coagulation. 24 The strong anionic nature and ability to complex with divalent cations, such as calcium, give polyphosphates properties that promote coagulation, increase thrombin-mediated factor V activation, factor XII and XI activation, and delay fibrinolysis through activation of TAFI (thrombin-activatable fibrinolysis inhibitor). Although the biology of polyphosphates in coagulation is under investigation, a surface-based or template mechanism may be particularly important, with distinct binding sites for protease assembly.
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Platelets and the Vascular Endothelium, Vascular Integrity, and Development
Platelets are essential in the formation and maintenance of blood and lymphatic vessels. During development and in the settings of inflammation, platelet ITAM signaling directs critical cellular interactions. 26 Under these specific settings, ITAM and hemi-ITAM signaling promotes vascular integrity. Platelets contain several ITAM pathways, including the collagen receptor GPVI that noncovalently binds to the Fc receptor γ chain, CLEC-2 (C-type lectin-like receptor 2), and Fc receptor γII A. The spectrum of events regulated by ITAM signaling is distinct from those governed by soluble agonists acting through GCPR (G-protein-coupled receptor) systems-both of which are essential regulators of platelet responses to vascular injury, as well as hemostasis and thrombosis.
The platelet CLEC-2 triggers platelet activation and aggregation through downstream signaling events, including activation of the Syk kinase-SLP76 signaling cascade. Among the ligands for CLEC-2 is PDPN (podoplanin)-a heavily glycosylated transmembrane protein expressed on the surface of lymphatic endothelial cells, fibroblastic reticular cells in lymph nodes, kidney podocytes, and neuroepithelial cells. [27] [28] [29] The lack of PDPN on vascular endothelium limits its access to CLEC-2 on circulating platelets. However, during development or in specific inflammatory settings, PDPN is exposed and accessible to platelet CLEC-2. During development, as lymphatic endothelial cells bud out from the cardinal vein to form primary lymph sacs, exposure of PDPN promotes CLEC-2-mediated platelet adhesion, which is essential for platelet accumulation necessary for blood-lymphatic separation 30, 31 and may be essential for maintaining lymphovenous junctions in adults. 32 Disruptions of these interactions in mice result in severe lymphatic defects. In addition to separating blood and lymphatic vessels, platelet CLEC-2 binding to Figure 1 . Schematic representation of contemporary platelet biogenesis and activation. Megakaryocytes derived from myeloid stem cells give rise to platelets. Several factors present or released from endothelial cells, including NO, prostacyclin, and ADPase, act to keep circulating platelets in a resting state. Platelets can be initially activated by several different triggers, including (but not limited to) adhesion to collagen via GP (glycoprotein) and the α2β1 integrin, vWF (von Willebrand factor) binding to GP Iβ/IX/V complex, and generation of thrombin at or near the platelet surface that signals through PARs (protease-activated receptors). These pathways elicit downstream activation of PLC (phospholipase C) isoforms to generate second messengers inositol 1,4,5-triphosphate (not shown) and DAG (1,2-diacylglycerol), which in turn link to pathways that drive secretion of alpha granule contents, including prothrombotic proteins Fg (fibrinogen) and vWF, as well as the secretion of dense granules to release several soluble platelet agonists, such as ADP and serotonin. Activation is reinforced by secreted ADP acting on the P2Y1 and P2Y12 receptors and the activation of the TP (thromboxane receptor) from TXA2 (thromboxane A2) generated from arachidonic acid (AA) released during the initial wave of platelet activation. Platelet aggregation occurs through Fg-mediated integrin αIIbβ3 interactions with adjacent activated platelets.
PDPN and subsequent downstream events drive the late stages of lymph node development 28, 33, 34 and stabilize endothelial venule integrity within lymph nodes. 34 Similar interactions of CLEC-2 and PDPN on supporting vascular cells, such as neuroepithelium, seem to be essential for proper maturation of cerebral vasculature, its integrity, and ability to prevent hemorrhage. 35 PDPN is also expressed on certain types of tumors, typically at the leading edge where it may direct migration and invasion. 36 Interactions between tumor cell PDPN and platelet CLEC-2 may trigger platelet activation and aggregation, promoting cancer-associated thrombosis and enhancing tumor metastasis. The potential role of CLEC-2 inhibition in the setting of malignancy-induced thrombophilia warrants further evaluation. 37 Synthetic phosphorothioate-modified CpG oligodeoxynucleotides, currently being exploited in clinical trials of anticancer treatment because of their potent immunestimulatory properties, may activate human platelets via the ITAM-coupled receptor and GPVI and could increase the risk for thrombosis after treatment. 38 Within the vasculature, platelets protect endothelial barrier function, particularly in the setting of inflammation 39 through incompletely understood mechanisms that seem to require ITAM signaling but not GPCR signaling. 40 In addition to physical interactions, platelets also promote vascular integrity through release of bioactive mediators. Platelets generate and release constitutively or in a stimulus-dependent manner several endothelial stabilizing factors, including S1P (sphingosine-1-phosphate; essential for barrier function), ADP, serotonin, VEGF (vascular endothelial growth factor), and thrombospondin. Although there are redundant sources for plasma S1P, platelet release with activation appears to be important during recovery from passive systemic anaphylaxis induced by immune complexes or with platelet-activating factor in mice to prevent vascular leak and death.
41 S1P, through the S1P receptor 1, also controls thrombopoiesis, proplatelet formation, and platelet count in mice. 42, 43 The interactions between platelets and the vascular endothelium are a tightly orchestrated events 44, 45 that typically begin with platelet tethering via PSGL-1 (P-selectin glycoprotein ligand-1) or GP Ibα with endothelial P-selectin (rolling), followed by subsequent firm adhesion to the vascular wall mediated through integrins and other adhesive molecules. In response to inflammatory or other stimuli, P-selectin rapidly translocates from membranes of storage granules (Weibel-Palade bodies) to the plasma membrane. Both GP Ibα and PSGL-1, which are constitutively present on platelets, recognize and bind to endothelial P-selectin to initiate loose bonds and platelet rolling along the endothelium. Firm adhesion of platelets to intact endothelial cells depends on platelet integrin αIIbβ3-binding fibrinogen bound to endothelial receptors ICAM (intercellular adhesion molecule) and αVβ3 and also through interactions with platelet-bound fibronectin and vWF. 44, 46, 47 Inflammatory cytokines, such as RANTES (regulated on activation, normal T-cell expressed and secreted) and CD40L (CD40 ligand), strengthen platelet adhesion to endothelial cells.
Along with endothelial P-selectin, ultralarge vWF can be released along activated venous endothelium 46 and promotes the accumulation of platelets like beads on a string. vWF is secreted from vascular endothelial cells and platelets, after stimulation by more than one mediators, including histamine, leukotriene D4, platelet-activating factor, vascular permeability factor, the terminal component of complement, epinephrine, fluid mechanical forces, factor VIIa, thrombin, and fibrin. In addition, Weibel-Palade bodies (containing vWF) are rapidly translocated to the cell surface after activation. The association of vWF with the luminal surface of endothelial cells may be mediated by vitronectin receptors αVβ3, GP Ib, or a constituent of the Weibel-Palade body itself. The nature (or stimulus) of release also carries important functional ramifications. Thrombin stimulates the appearance of high-molecular weight vWF multimers (not present in the circulation under normal circumstances) with increased functionality. Because vWF is synthesized and stored in both endothelial cells and platelets, released in response to their activation, and participates in sitespecific thrombosis, it may represent a multidimensional biomarker of underlying pathological events. The unfolding and stretching of vWF is enhanced in high-shear stress environments as a result of margination of platelets and platelet microparticles toward the vessel wall in large part by erythrocytes that migrate to the center of the vessel because of hydrodynamic interactions and the interaction of nonspherical and deformable objects underflow conditions. 48 Accordingly, both margination and stretching must occur before adhesion, and the functional properties of vWF are highly dependent on shear rate and the concentration erythrocytes. The ADAMTS13 proteolyses vWF to disrupt and attenuate platelet accumulation. In the absence of ADAMTS13, platelets can coalesce to form thrombi along the intact endothelial surface. Disruption in ADAMTS13 is a causal mechanism for thrombotic thrombocytopenic purpura, characterized by renal and neurological abnormalities, including stroke because of thrombotic microangiopathy.
Platelets and Inflammation
Platelets contribute to leukocyte rolling and extravasation in response to inflammatory stimuli. 49 The attachment of platelets to damaged or activated endothelium can serve as a nidus to recruit leukocytes ( Figure 2 ). Moreover, neutrophils adhered to inflamed endothelium scan the circulation for and attract activated platelets, and the binding of platelets to neutrophils provides essential feed-forward signals to propagate the inflammatory response. 50 Leukocytes form loose, transient tethers through P-selectin expressed on the activated platelet surface, with subsequently stable adhesion mediated by activation of leukocyte β2 integrins, including Mac-1, 51,52 which recognizes its ligand on the platelet surface GP Ibα 53 and may also interact with JAM-3 (junctional adhesion molecule-3), ICAM-2, fibrinogen bound to αIIbβ3, and HMWK (highmolecular-weight kininogen) bound to GP Ibα. 54 During this adhesive process, signaling events are triggered within both platelets and leukocytes to result in the release of addition molecules that influence the inflammatory cascade. 55 Leukocyte interactions with platelets result in immediate events, including activation of adhesion receptors, reactive oxygen species generation and thrombin formation, but also delayed responses such as alterations in gene expression and protein synthesis. Platelets and leukocytes participate in transcellular February 2, 2018 metabolism of arachidonic acid to generate novel mediators that either cell type alone could not generate. Tissue factor expression is also regulated by adhesive events between platelets and leukocytes, and activated platelets support thrombin generation. 56 Platelet chemokines 57 and platelet-derived microparticles (covered in greater detail in a subsequent section) that can serve as a delivery system for inflammatory proteins and small molecules 58 also promote inflammatory responses in experimental models.
Platelet-leukocyte heterotypic cell aggregates can be detected in the circulation and predict outcomes among patients with acute coronary syndrome (ACS) and after percutaneous coronary intervention (PCI). 59, 60 In the setting of ACS and PCI, platelet-leukocyte aggregates correlate with the inflammatory marker CRP (C-reactive protein) and with biomarkers of myocardial necrosis, such as troponin. 61, 62 Neutrophil accumulation in culprit coronary arterial sites of vascular injury is a predictor of adverse cardiovascular events, and an analysis of thrombi derived from 111 patients with ST-segment-elevation myocardial infarction (MI) undergoing primary PCI revealed that neutrophils were highly activated and formed aggregates with platelets that contributed to the scaffolds of these thrombi adherent to sites of plaque and vascular injury. 63 Similar analysis of late stent thrombus by PRESTIGE (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort) investigators, who analyzed 253 thrombus specimens consisting of 79 from patients with early (<30 days) stent thrombosis and 174 patients with late (>30 days) stent thrombosis, identified leukocyte infiltrates as hallmarks of both early and late stent thrombosis, with neutrophils representing the most prominent subset. 64 In addition, soluble P-selectin, which is largely released after PSGL-1 binding, is elevated in several conditions, including MI, 65 and in women, elevated levels predict future cardiovascular events. 66 In the SELECT-ACS trial of patients with ACS, the P-selectin antibody inclacumab given as a single dose of 20 mg/kg reduced cardiac injury, as determined by plasma levels of troponin I at 24 hours after PCI (P=0.05). 67 Patients receiving inclacumab <3 hours before PCI derived even greater benefit with significantly less myocardial damage (P=0.02). 68 Platelets release bioactive mediators that influence the function of surrounding cells and also exert systemic effects. A diverse assortment of biologically active cargo is released from intracellular granules on platelet activation. Platelet dense granules store the purine nucleotides ADP and ATP, which play key contributory roles in thrombosis, inflammation, ischemia-reperfusion injury, and potentially acute lung injury. 69 Platelet release of serotonin from dense granules modulates mitogenic and inflammatory responses and has been implicated in neutrophil rolling and adhesion to inflamed endothelium. 70 Finally, as described above, inorganic polyphosphates are major components of dense granules that are released during platelet activation and impact coagulation and inflammation differentially based on the size of the polyphosphate polymer. 23, 71 Polyphosphates may play a particularly important role in the interface between coagulation and inflammation. Bae et al 72 have shown that polyphosphates stimulate an intracellular proinflammatory response through nuclear factor-κB. Given polyphosphates' short half-life in peripheral blood with prompt degradation via plasma phosphatases, existing regulatory mechanisms that become either dysfunctional or overwhelmed in active disease states will be an area of interest for future investigation. Platelet α and dense granules contain adhesive proteins, coagulation, mitogenic and angiogenic factors, CXC and CC chemokines, and other factors. One of the most abundant α-granule proteins, PF4 (platelet factor 4), may influence both neutrophils and macrophages and has been implicated in atherosclerosis and vascular smooth muscle cell (SMC) responses after injury. PF4 acts, at least in part, through Kruppel-like factor 4 to transcriptionally regulate SMCs, reduce their differentiation, and promote an inflammatory phenotype. 73 Figure 2. Role for platelets in inflammation and response to pathogens. At sites of damaged or inflamed endothelium, platelet adhesion occurs through various interactions, such as with exposed subendothelium, P-selectin expression on activated endothelium, and release of ultralarge vWF (von Willebrand factor). Adherent platelets, in turn, recruit white blood cells (WBCs), which can subsequently transmigrate across the endothelium. Heterotypic cell interactions between platelets and WBCs or red blood cells (RBCs) can occur and are associated with increases in systemic inflammation. Activated platelets can trigger the release of neutrophil extracellular traps (NETs), which contribute to microbial clearance and clot formation. Platelets also interact with viral and bacterial pathogens to contribute to their clearance and respond to gut microbiota that can modulate platelet function.
Platelet Vesicles
Human blood contains numerous phospholipid bilayer membrane covered vesicles that are engaged actively in cell-cell communication and regulatory functions. 74 Extracellular vesicles include exosomes (30-100 nm) and microvesicles (100-1000 nm), also referred to as microparticles, and can be found in most biological fluids and contain a variety of molecules, including proteins, lipids, RNA, and miRNA. The original work by Warren et al 75 detailed the release of extracellular vesicles into the extracellular space after platelet activation and adhesion to a vessel wall. 76 Several platelet-specific markers have been identified and include CD9, CD63, TSG101 (tumor susceptibility gene 101), flotillin, and ALIX (ALG2-interacting protein X). 77 Platelet exosomes are likely of endosomal origin and subsequently released with the fusion of multivesicular bodies to the plasma membrane. 78 By contrast, microvesicles are released with budding of the plasma membrane at specific sites referred to as microdomains. 79 Using varied centrifugation methods, Savelyeva et al 80 identified vesicles of platelet and T-cell origins. They also performed high throughput sequencing of RNA contained within the vesicles and identified miRNAs. There were nonvesicle-related fragments of other cellular RNAs, including rRNAs, tRNAs, IncRNAs, mRNAs, and RNAs encoded by mtDNAs, highlighting the diversity of RNAs within the circulation. Platelet microvesicles can be internalized by neutrophils through a highly regulated mechanism that augments inflammation. Specifically, microvesicles and their RNA, miRNA, and other cargo are internalized by activated neutrophils within the endomembrane system through 12-hydroxyeicosatetranoic acid and platelet-type12-lipoxygenase. 81 van der Meijden et al 82 have demonstrated that microvesicles from platelets and erythrocytes propagate coagulation by exposing phosphatidylserine and initiating thrombin generation independently of tissue factor in a factor XII-dependent manner. 83 By contrast, monocyte-derived microvesicles trigger coagulation predominantly via tissue factor.
Platelet miRNA
Individual variations according to race, gene mutations, acute illness, and chronic disease are associated with changes in genetic codes and their regulation within megakaryocytes. In turn, changes at the molecular level within megakaryocytes are transferred into developing platelets that are then released into the circulation where they influence responses at the cellular and tissue levels. 84 A brief overview of gene expression and regulation is provided below. miRNAs are small, noncoding, regulatory RNAs that play a pivotal role in gene modulation and expression, including within cardiovascular disease 85 and platelet physiology. 86 Platelets retain megakaryocyte-derived miRNAs. Maximally activated platelets retain a capacity for protein synthesis and convert precursor miRNAs to regulate platelet receptor signaling. miRNAs contribute to normal megakaryocytopoiesis, proplatelet formation, and biological activity. The role of platelet miRNA may be particularly important for endothelial cell, myocyte, SMC, fibroblast, leukocyte, and molecular signaling that occurs in thrombosis, inflammation, and malignancy-associated processes. 87 miRNAs participate in lineage specification of mammalian multipotent cells. Lu et al demonstrated that miR-150 drives megakaryocyte differentiation through transcription factor MYB (V-MYB myeloblastosis viral oncogene homolog) signaling. miR-503 has been reported to inhibit platelet-derived growth factor-induced aortic vascular SMC proliferation and migration-a pivotal process in atherosclerotic disease progression. 88, 89 The resulting effects of miRNAs on megakaryocytes and platelet biology were analyzed in 79 patients with thrombocytosis and a diagnosis of essential thrombocythemia. 90 A previously uncharacterized miR-490 displayed aberrant and decreased expression under translational control in conditions associated with exaggerated megakaryocytopoiesis, supporting specific miRNAs in lineage commitment during normal dysregulated hematopoiesis.
Dysregulated miRNA expression contributes to a variety of diseases. The miR-146 family has a distinct expression pattern in hematopoiesis and is associated with inflammation and autoimmune diseases. An mRNA receptor tyrosine kinase, PDGF-receptor α, is the target for miR-146b and along with the transcription factor, GATA-1 (GATA-binding protein 1), forms a regulatory circuit for megakaryocyte differentiation. Platelet-secreted miR-223 promotes endothelial cell apoptosis induced by glycation end products through insulin-like growth factor. The underlying mechanism involves the release of miR-223 containing microvesicles after platelet activation. Stimulation of platelets with thrombopoietin augments microvesicle release and also increases the concentration of miR-223 packaged within the microvesicles themselves. Incubation of platelet microvesicles with human umbilical endothelial cells has demonstrated transfer and delivery of miR-223. Last, the proapoptotic effect of miR-223 was nearly abolished with depletion using an anti-miR-223 antisense oligonucleotide.
Nagalla et al 91 performed genome-wide RNA profiling in 19 healthy subjects to determine the association between platelet miRNA and platelet reactivity. A total of 284 miRNAs were identified. Seventy-four miRNAs were differentially expressed in subjects who had robust platelet aggregation in response to epinephrine. Three distinct mRNA-micro-RNA pairs were identified in these subjects: miR-200b-PRKARZB (protein kinase cAMP-dependent type II regulatory subunit beta); miR-495-KLHL5 (Kelch-like 5), and miR-107-clock, each with a negative correlation. All 3 miRNAs knocked down protein expression from the target mRNA.
Platelet-rich plasma typically contains the greatest amount of miRNA as compared with platelet-poor plasma and serum, 85 suggesting that platelets are a rich source. miR-223 is the most differentially expressed miRNA from platelet-rich plasma and also has discriminating value compared with serum. Other abundant miRNAs of platelet origin include miR-197, miR-221, miR-191, miR-199a-3p, miR-454, miR-24, miR-146a, miR92a, miR-let-7a, and miR-195. Antiplatelet therapy (aspirin, clopidogrel, or dipyridamole) given to either healthy volunteers, patients with diabetes mellitus, or patients with symptomatic carotid atherosclerosis reduced miR-126, miR-150, miR-191, and miR-223 as early as 48 hours from drug initiation. Changes in miRNA levels correlated with the degree of platelet inhibition February 2, 2018 based on light transmittance aggregometry and transcranial Doppler-detected microembolization. Although the mechanisms responsible for the decrease in circulating platelet miRNA levels after antiplatelet therapy are not fully known, reduced microvesicle shedding on activation is a possibility. The miRNA profile in circulating blood may also be influenced by associated disease states and conditions, including MI wherein exosome release of miR-1, miR-133a, miR-208a, and miR-499 after myocyte injury is the primary mechanism. 92 The transfer of miRNA from one cell to an adjacent cell, including from platelets to leukocytes and endothelial cells among others, occurs through membrane vesicles ranging in size from 30 (exosomes) to 1000 (microvesicles) nm. 93 Nonvesicle transfer has also been described.
Platelets and Neutrophil Extracellular Traps
In response to strong stimulation, neutrophils release neutrophil extracellular traps (NETs) that consist of DNA and histones in a process that involves histone citrullination by peptidylarginine deiminase-4, chromatin unwinding, breakdown of nuclear membranes, and cytolysis. 94, 95 A key function of the extracellular chromatin material is to entrap and confine microbes to promote their destruction.
Platelets can trigger NET formation and may also bind to histones to form platelet-NET attachments (Figure 3 ). Histones activate platelets through TLR (toll-like receptor)-dependent mechanisms to generate the release of polyphosphates, 96 which, in turn, amplify coagulation. Platelet-neutrophil interactions facilitate NET formation. Etulain et al 97 induced NET formation by thrombin-activated platelets and documented a role for P-selectin and PSGL-1 in the process.
NETs can promote prothrombotic and proinflammatory signaling. Several reports indicate a key role for neutrophils and NETs in venous thrombosis in animal models. 95, 98, 99 NETs themselves can initiate platelet activation and thrombosis. Thrombus NET burden in culprit arteries of patients presenting with ST-segment-elevation MI correlated directly with infarct size and inversely with ST-segment resolution. 63 Nucleosomes, double-stranded DNA, myeloperoxidase, and myeloid-related protein 8/14 were increased in the plasma of these patients. The interdisciplinary global European effort (PRESTIGE) also identified NETS in 23% of all samples of late stent thrombus, with equal representation in specimens from patients with early and late stent thrombosis. 64 In sepsis, NET-associated molecules, including DNA, histones, and tissue factor, promote thrombin generation. 100 NETs have been implicated in experimental transfusion-related acute lung injury, where their formation seems to be triggered by activated platelets. 101 Analysis of material obtained by aspiration of coronary thrombi identified NETs, histone H1, myeloperoxidase, and neutrophil elastase in samples obtained from fresh clot or after thrombolysis. 102 NET formation may also occur in systemic lupus erythematosus and contribute to the premature cardiovascular disease that occurs frequently in these individuals. 103 Taken together, these findings demonstrate that NETs serve as an important link between immunity and thrombosis and support a basis for considering them as a novel therapeutic target for thrombosis prevention and treatment. Indeed, in animal models, DNase1 treatment and peptidylarginine deiminase-4 deficiency dramatically protect against venous thrombosis.
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An ability to target NETs, platelets, or nucleic acids found within a developing thrombus could represent a change Figure 3 . Platelet participation in neutrophil extracellular trap formation (NETosis). Activated platelets interact with neutrophils via platelet P-selectin and neutrophil PSGL-1 (P-selectin glycoprotein ligand-1), with interactions stabilized by a series of secondary adhesion interactions, including the ones mediated by platelet GP (glycoprotein) Ib and leukocyte Mac-1 (αMβ2). This interaction can contribute to trigger the release of NETs, consisting of chromatin containing citrullinated histones complexed with antimicrobial proteases, such as elastase and myeloperoxidase, in a process called NETosis. NETs serve to enhance the clearance of pathogens. They also contribute to clot formation by forming a mesh with platelets and fibrin and accumulating coagulation factors, such as tissue factor (TF).
in the treatment of thrombotic disorders and conditions. Preliminary evidence from Jain et al 83 suggests that an approach to therapeutics based on binding of cationic polymers is feasible. The investigators evaluated 6 agents known to bind nucleic acids for their ability to attenuate nucleic acidmediated activation of TLRs: polyphosphoramidate polymer (PPA-DPA), polyamidoamine dendrimer, 1,4-diaminobutane core-PAMAM-G3 (polyamidoamine dendrimers-generation 3), poly-L-lysine, CDP (β-cyclodextrin-containing polycation), HDMBr (hexadimethrine bromide), and protamine sulfate. All of the compounds except protamine sulfate inhibited TLR3 activation by synthetic dsRNA, polyinosinic-polycytidylic acid as measured by TNF-α (tumor necrosis factor-α) and IL-6 (interleukin-6) production, and CD80 expression. Moreover, 3 of the cationic polymers, CDP, HDMBr, and PAMAM-G3, inhibited the ability of synthetic CpG DNAs (CpG 1668) to activate TLR9. Similarly, these 3 polymers inhibited the ability of ssRNA-lipid complexes (ssRNA40) to activate TLR7. Such cationic polymers are specific for nucleic acid-mediated activation of the TLRs. They subsequently were able to show that nucleic acid-binding polymers neutralized extracellular inflammatory and prothrombotic nucleic acids, rather than directly inhibiting nucleic acid-sensing TLRs.
Platelets, Pathogens, and Host Response to Infection
Platelets can be influenced by gut microbes, through their generation of nutrient-specific byproducts. Microbial metabolism of phosphatidylcholine, choline, and carnitine can liberate trimethylamine that is converted by hepatic flavin monoxygenases to trimethylamine N-oxide (TMAO). In the GeneBank Study of >4000 participants, TMAO levels correlated with thrombotic risk. 105 To determine whether TMAO could directly affect platelet function, Zhu et al 106 examined its impact on platelet function in vitro and on experimental thrombosis. Both TMAO and dietary choline enhanced agonist-induced responses and promoted experimental thrombosis. Intriguingly, cecal microbial transplantation between strains of mice with high or low plasma TMAO altered time to thrombosis, suggesting that platelet reactivity and thrombosis potential can be transmitted by bacteria.
In turn, platelets can both protect or promote immunemediated responses to pathogens. 107 Platelets bind to several different microbes, either through direct interactions mediated by platelet Fc receptors or indirectly via plasma protein bridges. 108 Similar to agonist-activation, the binding of pathogens can trigger granule cargo release 109 and liberation of platelet microbial proteins and peptides, including PF4, RANTES, and fibrinopeptide B. Platelets can eliminate Escherichia coli through opsonization by IgG, 110 internalize pathogens, such as Staphylococcus aureus 111 and HIV, and interact with Plasmodium falciparum parasite-infected red blood cells to augment the killing of malarial parasites in mice. Either thrombocytopenia or aspirin increase susceptibility to malarial infection in mice. 112 Thus, in several clinical contexts, platelets may play a protective role in the host responses, and their responses may be modified by gut microbiota. 113 Platelets respond to the glycolipid endotoxin or lipopolysaccharide in the outer membrane of Gram-negative bacteria. Platelets express all of the necessary machinery to recognize lipopolysaccharide, including TLRs 114 and the adaptor protein MyD88 (myeloid differentiation primary response gene). 115 Although reports of the effect of lipopolysaccharide on platelet function are not consistent, 115 -119 lipopolysaccharide appears to potentiate the effect of other platelet agonists. 115 Lipopolysaccharide injection rapidly provokes thrombocytopenia because of trapping of platelets in the microvasculature. [120] [121] [122] Indeed, in animal models of sepsis, platelets accumulate in lung, liver, and other tissues 120 where they contribute to organ damage. Antiplatelet therapy prevents thrombocytopenia, reduces fibrin accumulation in lung and cytokine production after lipopolysaccharide challenge, 121, 123, 124 and attenuates liver injury in a mouse model of polymicrobial peritoneal contamination. 125, 126 Among the mechanisms responsible include GP Ibα-mediated platelet activation and promotion of platelet-leukocyte binding 127, 128 and exposure of CLEC-2 ligands in injured organs, such as liver. During sepsis, alternative splicing of tissue factor occurs in platelets, 129 which augments thrombogenicity. 130 Although the above findings suggest that platelets promote organ dysfunction in the context of infection, thrombocytopenia in sepsis is a strong predictor of poor outcomes for reasons that are not well understood. [131] [132] [133] In critically ill patients, thrombocytopenia correlates with multiorgan failure and death, and a decline in platelet count, even in the absence of overt thrombocytopenia, portends a worse outcome. 133 Low platelet counts may reflect disease severity, underlying disseminated intravascular coagulation, and tissue/organ injury. This is an active area of investigation, and regulation of protein kinase A activity in platelets may be a target to prevent thrombocytopenia because of apoptosis in settings of bacterial infection and other conditions. 134 Platelet sequestration in pulmonary tissue is a key feature in inflammatory states and may contribute to acute lung injury and acute respiratory distress syndrome. 135 At platelet counts <10% of normal levels (ie, <20 000/mm 3 ), disruption in the endothelial barrier, particularly in the setting of inflammation, 39 can occur and increase vascular permeability, 136 which in the lung can exacerbate acute respiratory distress syndrome. Platelets have been implicated in acute lung injury by direct recruitment of neutrophils to injured vessels and through the release of granule contents, microvesicles, platelet-activating factor, and other mediators. 137 In mice, transfusion of platelets attenuates damage from lipopolysaccharide or bacterial challenge, in part, by attenuating macrophage-dependent inflammation via the PTGS (prostaglandin-endoperoxide synthase) 1/PTGS2/EP4 (prostaglandin E receptor 4)-dependent pathway. 138 Retrospective and observational studies in critically ill subjects suggest that antiplatelet therapy may improve clinical outcomes, especially the risk of acute lung injury. 124 However, in the LIPS-A trial (Lung Injury Prevention With Aspirin), aspirin (325 mg followed by 81 mg daily) administered within 12 hours of hospitalization to individuals at risk for acute lung injury had no effect on development of acute respiratory February 2, 2018 distress syndrome. 139 Intriguingly, retrospective analysis of the PLATO study (Platelet Inhibition and Patient Outcomes), in which patients with ACS were randomized to ticagrelor or clopidogrel, indicated that the mortality advantage of the more potent antiplatelet agent ticagrelor occurred after pulmonary events (eg, lower respiratory tract infection, pneumonia, and respiratory failure).
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Platelets in Atherothrombosis
Many of the molecular constituents that mediate leukocyteendothelium interactions in atherosclerosis also coordinate leukocyte attachment and transmigration across layers of adherent platelets and regulate platelet-endothelial interactions. In animal models, strong evidence links these platelet-mediated cellular events to the development of atherosclerosis. Infusion of activated platelets into hyperlipidemic mice promotes the development of atherosclerosis. 142 The major platelet-adhesive receptors P-selectin, 143, 144 GP Ibα, 145 and integrin αIIb 146 have all been linked to experimental atherosclerosis in mice, as have key platelet activation pathways, including those leading to Rap-1-mediated integrin activation, PTGS1, and possibly P2Y12 receptor signaling. 146, 147 An atherosclerosis mouse model demonstrated that prolonged antibody blockade of GP Ibα led to reduced arterial leukocyte accumulation in carotid arterial intima and subsequent reduced atherosclerosis lesion formation. 145 CLEC-2 ligands on vascular SMC may promote platelet adhesion and activation leading to atherosclerosis, 148 and adhesive proteins that attract platelets, such as vWF, may also have a role in atherogenesis. 149 Platelet adhesion activates endothelial cell nuclear factor-κB and its regulated genes, many of which play key roles in plateletleukocyte-endothelium-extracellular matrix molecular events that support inflammatory and proatherogenic phenotypes. Cytokines critical for the development of atherosclerosis are generated during platelet-leukocyte and platelet-endothelial interactions. Together, these events contribute to lesion maturation by stimulating SMC and fibroblast proliferation and promotion of collagen synthesis, among others.
In contrast to the strong data supporting a role for platelets in the development of atherosclerosis in animals, evidence in support of a role for platelets in human atherogenesis is less compelling. Systemic platelet activation in humans has been described in a variety of atherosclerosis disease phenotypes; however, antiplatelet agents do not unequivocally inhibit disease progression. One possible explanation is that platelets contribute in early lesion formation but not in more advanced stages in human disease, especially after an initial atherosclerosis-associated clinical event. 150 In experimental models of arterial injury, platelet responses are coordinated over time and space to promote thrombosis, 149 and the growing thrombus shapes its microenvironment to create a dense core of highly activated platelets surrounded by a loose shell of less-activated platelets. [151] [152] [153] [154] The interior of intact atherosclerotic plaques is rich in components that are highly thrombogenic (eg, collagen types I and III, tissue factor, and oxidized and bioactive lipids) and if exposed, generates a thrombotic response characterized by rapid platelet accumulation stabilized by fibrin formation that provides longevity of the early and fragile platelet thrombus. 155 As a result of reduced flow caused by the platelet-rich thrombus at the plaque rupture site, an erythrocyte-and fibrin-rich thrombus may form and propagate proximally and distally within the artery. 155 The consequences of arterial thrombosis include such events as MI and stroke, which may represent dynamic processes with thrombosis, repeat thrombosis, and thrombolysis along with embolization-each step occurring in a dynamic fashion and contributing to intermittent flow obstructions.
Platelets in Venous Thrombosis
Experimental models also support a role of platelets in venous thromboembolic disease. In a venous thrombosis model initiated by restriction of blood flow without endothelial disruption, platelets are critical for thrombus propagation by promoting GP Ibα-mediated leukocyte recruitment, NET formation, and coagulation factor XII-dependent thrombin generation. The recruited leukocytes can trigger massive fibrin formation via blood cell-derived tissue factor. Several groups have demonstrated that disruption of NETs with DNase1 treatment and peptidylarginine deiminase 4-deficiency dramatically protects against venous thrombosis. Platelets may also be a crucial source for damage-associated molecular pattern HMGB1 (high-mobility group box 1 protein), which is a key regulator of sterile inflammation and also regulates thrombus formation by activating receptor for advanced glycation end products, TLR2 on monocytes to trigger monocyte-derived tissue factor and cytokine release 156 and by eliciting TLR4-and MyD88-dependent recruitment of platelet guanylyl cyclase and activation of the cGMP-dependent protein kinase I. 157 Mice deficient in CLEC-2 are protected from venous thrombosis, 158 suggesting a role for upregulation of PDPN or other CLEC-2 ligands in the venous wall as a trigger for platelet activation. Two randomized trials of venous thromboembolism prevention demonstrated a modest benefit of aspirin therapy (≈30% risk reduction versus placebo), lending clinical support for a role of platelets in venous thrombosis aspirin.
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Platelets and Tissue Regeneration
The role of platelets in wound and bone 161 healing and tissue repair 162 has been extensively characterized with evidence that they both promote damage and facilitate recovery. 163 Platelet derivatives, such as platelet-rich plasma, platelet gel, plateletrich fibrin, and platelet eye drops, are under investigation for benefit in tissue repair and wound healing. 164 Probably, the most striking example of their role in reparative process occurs in the liver, where platelets promote hepatic regeneration, 165 at least in part, through release of serotonin. 166 Regeneration can also occur through binding endothelial and Kupffer cells and traversing the sinusoids to interact directly with the hepatocytes and stimulate proliferation through release of HGF (hepatocyte growth factor), VEGF, IGF (insulin-like growth factor) 1, and other mediators.
Platelets recruit and promote the differentiation of progenitor and stem cells that can influence reparatory processes. 167 For example, they express substantial amounts of SDF-1 (stromal cell-derived factor-1) and recruit CD34+ cells and promote their differentiation into endothelial cells.
168-170
Development and Pipeline of Platelet-Directed Therapeutics
The physiology of platelets as summarized above serves as a reminder of the scientific community's advances in the field but also underscores numerous untapped opportunities. Far beyond traditional constructs of hemostasis and thrombosis, with the latter dominating the pharmaceutical landscape during the past 3 decades for the prevention and treatment of MI and ischemic stroke, the intricate role of platelets in psychosocial stress responses, inflammatory disorders, autoimmune diseases, tissue remodeling, and chronic illnesses opens the door to diagnostic platforms using blood as a reporter tissue, new therapeutic targets and solving puzzles of pathobiology and natural history across a continuum of human health and disease. Although one could also focus on understanding the potential expanded properties of existing platelet inhibitors, the challenge has and likely will remain the risk of bleeding. A contemporary perspective of platelet inhibition will include antithrombotic agents that minimize bleeding risk and nonthrombotic indications. 171 The success of αIIbβ3 inhibitors, approved for human use in the mid-1990s, in reducing ischemic events after PCI established the viability of developing platelet-specific therapies. The FDA-approved αIIbβ3 inhibitors have intravenous formulations and are associated with major bleeding and thrombocytopenia that limits their use. Initial attempts to generate orally active αIIbβ3 inhibitors resulted in drugs that elicited conformational changes in the integrin and that had partial agonist effects. A series of oral αIIbβ3 inhibitors failed to demonstrate benefit in several large clinical trials, and some were associated with increased mortality. Currently, efforts are underway to develop small-molecule αIIbβ3 inhibitors that lack conformational effect on the integrin, based on detailed understanding of its molecular structure.
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GPCRs
As described above, platelet GPCRs play a pivotal role in controlling responses. Many of the FDA-approved platelet-directed therapies target one or more of these signal transduction pathways, including ticagrelor, clopidogel, prasugrel, ticlopidine, and cangrelor, that target the platelet P2Y12 purinergic receptor and vorapaxar that blocks thrombin-mediated PAR-1 receptor activation. The latter strategy has been limited by heightened risk of bleeding. Ongoing work seeks to validate new GPCR signaling pathways as targets and also to develop new approaches to validated receptors. A small-molecule antagonist of the PAR-4 receptor has been studied in preclinical models, 174 with the hope that targeting PAR-4 will result in less bleeding than occurs with PAR-1 antagonism. Cell-permeable pepducin therapy is being investigated as a strategy to inhibit function of PAR-1 or PAR-4 receptors. 175, 176 Thromboxane receptor antagonism has been explored as a target in diabetics. 177 Additionally, drugs that directly affect G-protein function have been developed, 178 and downstream signaling pathways have been suggested as possible targets. 179 The attractive nature of GPCRs as a target or means to modify, attenuate, or fully inhibit platelet function related to thrombosis must be tempered by the recognition that these pathways operate in multiple organ systems and regulate a variety of vital physiological functions. In addition, targeting new receptor pathways, on top of standard of care therapy, may be accompanied by increases in bleeding, as has been observed when either PAR-1 antagonism or direct acting oral anticoagulants are added on to dual antiplatelet therapy. A key to drug development to promote antithrombotic benefits and to avoid unwanted and systemic effects may be achieving platelet-and patient-specific modulation through rationale, choice, and design of antiplatelet therapy rather than simply stacking on drugs from different therapeutic classes.
Alternatively, or in a complementary fashion, GPCR inhibition could be used to reduce tissue injury after stroke or MI. For example, GPR17 (G-protein-coupled receptor 17), present in high concentrations within the heart, brain, and kidneys, has been shown to influence ischemic damage in several models of ischemic injury. Zhuo et al 180 synthesized several new GPR17 ligands based on the structure of cangrelor and modified adenosine nucleotides. Several of these compounds, including 6-iodopurineriboside, N6-methyladenosine, N6-cyclopentyladenosine, nucleoside-5′-monophosphates, nucleoside-5′-diphosphates, and nucleoside-5′-triphosphates, have been shown to bind GPR17 with high affinity. Further investigation will be required to determine whether site-specific inhibition will favorably impact the response to tissue injury.
181
GPVI/Platelet Collagen Receptor as Therapeutic Target
Bhunia et al 182 developed a small-molecule inhibitor targeting the GPVI receptor involved with collagen-mediated platelet activation and adhesion in the context of high-shear conditions as would be encountered in arterial thrombosis. 183 This particular platelet receptor enjoys appeal because of its relatively restricted expression on megakaryocytes and platelets and the possibility, based on human platelet GPVI mutations and deficiency states, that targeted therapy would not be associated with serious bleeding. The investigators describe a new class of 2, 3 disubstituted tetrahydro pyrido indole that prevent collagen-mediated platelet aggregation. In addition to 2, 3 disubstituted tetrahydro pyrido indole that prevent collagenmediated platelet aggregation, other drugs targeting the GPVI receptor include snake venom metaloproteinase, 183 human monoclonal antibodies, 184 and GPVI-Fc fusion proteins. 185 The latter is furthest along in clinical studies, with revacept currently being examined in phase II trials in patients with stable coronary artery disease undergoing PCI and in patients with symptomatic carotid stenosis.
PDI
PDI (protein disulfide isomerase)-an endoplasmic reticulum protein involved in disulfide bonding-is released from platelet and vascular cells where it contributes to thrombus formation through imprecisely understood mechanisms that may involve factor V and other PDI substrates. 186 Antibodies, small-molecule inhibitors, and genetic deficiency of PDI prevent platelet-dependent thrombosis in experimental models. PDI small-molecule inhibitors include glycosylated quercetins, such as quercetin-3-rutinoside (also known as rutin), that February 2, 2018 are found in fruits and vegetables epidemiologically associated with lower cardiovascular deaths. In healthy individuals, the quercetin analog isoquercetin (1000 mg oral) results in sustained inhibition of PDI activity in plasma, reduced platelet-dependent thrombin generation, and lower platelet factor Va generation. 187 Isoquercetin ingestion also lowered ex vivo thrombin generation in subjects with antiphospholipid antibodies and elevated baseline thrombin production.
187
Connexins and Pannexins
Under normal physiological conditions, connexins and pannexins function as hemichannels or gap junctions that minimize platelet aggregation. By contrast, vascular injury with exposure of the extracellular matrix prompts platelet aggregation. Several hypotheses have been suggested: after stable platelet adhesion to matrix proteins, connexins may facilitate formation of gap junctions and allowing cAMP trafficking between adjacent platelets. Pannexins, in particular Panx1, contributes to granule-independent ATP release, calcium influx through purinergic platelet receptors, and amplifies aggregation. 188, 189 The relatively recent discovery that connexins and pannexins are linked to platelet aggregation opens the door to a new class of pharmacotherapies. 188 After GPVI binding to collagen, Src kinase phosphorylation facilitates pannexin-1 channel opening and ATP release, which, in turn, enhances intracellular calcium concentration in both platelet activation and aggregation. There are several pannexin-1 inhibitors that have been developed for other conditions-these include mefloquine, probenecid, and carbenoxalone among others. The role of connexins in platelet aggregation requires further investigation; however, there are several possible mechanisms. The first follows stable platelet contact with either another cell or damaged vascular surface wherein gap junctions are formed and cAMP trafficking occurs. The second possible mechanism includes hemichannel-mediated communication between platelet-platelet aggregates and activation of P2X1 (purinoceptor P2X1) receptors.
Regulatable Platelet Inhibitors
An ability to control either the degree or duration of platelet inhibition using antidote-controlled drug platforms has been an area of increasing interest. Our group used large libraries of RNAs that are screened by combinatorial chemistry methods to isolate RNA ligands, also known as aptamers, against a variety of target molecules, including platelet receptors and binding proteins. We have developed several RNA aptamers that bind vWF, primarily domain C, with high affinity and inhibit thrombosis in vivo. 190, 191 Complementary antidotes successfully reversed antiplatelet activity in a dose-dependent fashion and limited blood loss and surgically challenged animals. We think this particular platform of regulatable platelet antagonists will be particularly attractive to clinicians in the acute care setting where bleeding and other complications are more likely to occur. Our group continues to actively investigate vWF as a target for inhibition during acute thrombotic settings using antidote-based aptamers. We have optimized the structure and function of the aptamer and antidote using structure-predictive modeling and iterative aptamer truncation strategies while preserving the aptamer's structure and function, rationally designed and evaluated >100 variants of our lead vWF aptamer and synthesized truncates and tested their ability to bind to vWF and inhibit platelet function ex vivo and in vivo. Last, we evaluated 5 formulations of vWF aptamer (unpublished data). Our approach to aptamer biochemistry and drug development does not use a phosphorothioate backbone, thereby avoiding several adverse effects that have been reported previously, such as systemic reactions and platelet activation. 38, 192 We are particularly interested in the role that vWF plays in cell signaling, fibrosis, postischemic inflammation, microangiopathies, and NET binding and functionality in acute infections and tissue injury. [193] [194] [195] The PEGylated aptamer that targets vWF A1 domainplatelet GP Ib interactions, ARC1779, reduced cerebral microembolization, as detected by Doppler signal, in patients undergoing carotid endartectomy. 196 This drug is no longer under development.
Drug Development: In Vitro and Ex Vivo Testing Platforms
The development of platelet-directed therapies typically begins with a biologically relevant and functional target, such as a platelet receptor as discussed previously. Although the safety and efficacy profiles of any treatment strategy must ultimately be determined in the context of carefully designed and conducted clinical trials, the quest for precision medicine should include testing and conditions that are unique to a given condition. Platelets are most operative in high or variable shear rates. Prior investigations have suggested the following: low shear (100-1000 s −1 ) is primarily determined by fibrinogen, coagulation proteins, and platelets, specifically GP IIb/ IIIa; moderate shear (1000-4000 s −1 ) is primarily governed by GP Ib, GP IIb/IIIa, and insoluble agonists, such as thromboxane A2 and ADP; and finally, high or pathological flow (>4000 s −1 ), often found in areas of advanced atherosclerosis or ruptured plaque, is governed by GP Ib and vWF. 197 Employment of high throughput, low-volume microfluidic systems to mimic platelet-dependent pathological conditions has gained traction during the past several years given its ability to reproduce a variety of conditions of flow that cannot be characterized in static or previously used flow chambers. For example, soft lithography and micromilling fabrication has been used to recapitulate protein micropatterning of proteins exposed after localized vascular injury and the construction of complex flow environments that are often seen in atherosclerosis and thrombosis. These systems can also be modified and customized to a variety of blood-specific variables, including red blood cell count, white blood cell count, presence of inflammatory mediators, and acute phase proteins, and used to test varying treatments and doses.
The interface between platelets, endothelial cells, and leukocytes is highly relevant for understanding the mechanistic basis of atherosclerosis, thrombosis, and vascular disorders. Although in vitro studies of cellular crosstalk may provide insights, an important element of these interactions is flow. 198 Platelet-platelet interactions and platelet surface interactions are influenced by channel size and the relationship between height and width (aspect ratio), with values <0.2 believed to represent an ideal dimension for constant shear stress and laminar flow. Under optimal conditions, erythrocytes remain in the center of a flow chamber, and platelets are moved toward the wall. Accordingly, having erythrocytes in the study sample is important to reproduce physiological conditions, as are divalent cations, including calcium and magnesium 199 
Delivery Systems
In many clinical conditions with platelet-dependent intravascular thrombosis, localized as compared with systemic therapy is fundamentally attractive and could facilitate efficacy while minimizing the potential risks associated with systemic alteration of platelet adhesion, activation or aggregation. For example, Malloy et al 200 developed a shear stress sensitive release of eptifibatide using phosphatidylcholine-based nanocapsules (2.8×10 12 ; liposomes) in microfluidic blood perfusion assays. They were able to show that shear triggered nanocapsule delivery inhibited in vitro thrombus formation specifically in conditions above a shear rate of 1000 s −1 , while leaving thrombus formation under physiological shear conditions unaffected. Thrombosis was prevented in an in vivo model of ferric chloride vessel wall injury. In addition, mice infused with shear sensitive antiplatelet nanocapsules did not demonstrate a prolonged bleeding time. The circulating halflife of the phosphatidylcholine-based liposomes was on the order of several hours. This property may be ideal to deliver therapeutic agent selectively at a critical period of time. It is conceivable that liposomes could also be used to deliver other therapies, such as prostacyclins and analogue derivatives, multidrug resistance protein 4 inhibition, or microsomal prostaglandin E synthase-1 inhibition.
201
Conclusions
Platelets, although anuclear, are complex, biologically active circulating cells that participate in hemostasis, thrombosis, tissue regeneration, wound healing, inflammatory responses, and immune regulation. Structure-function relationships and the highly intricate crosstalk between platelets and other cells at the biochemical and molecular levels represents a portal for understanding human health and disease and a solid foundation for translation to new diagnostic platforms and therapeutic strategies.
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